CATX · Perspective Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $21.37M | - | $20.34M | $16.62M | $14.33M | - | $12.03M | $9.28M | $7.45M | - |
| SG&A | $6.99M | - | $7.73M | $7.71M | $7.84M | - | $6.97M | $5.51M | $5.88M | - |
| Total Operating Expenses | $28.36M | - | $28.07M | $24.33M | $22.17M | - | $19.00M | $14.79M | $13.33M | - |
| D&A | $1.13M | - | - | - | $356.0K | - | - | - | $346.0K | - |
| Operating Income | ($28.28M) | - | ($27.86M) | ($24.04M) | ($21.83M) | - | ($18.63M) | ($14.26M) | ($13.01M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($26.19M) | - | ($25.97M) | ($21.48M) | ($18.18M) | - | ($15.12M) | ($11.70M) | ($12.28M) | - |
| EPS - Basic | ($0.25) | - | ($0.35) | ($0.29) | ($0.25) | - | ($0.21) | ($0.18) | ($0.20) | - |
| EPS - Diluted | ($0.25) | - | ($0.35) | ($0.29) | ($0.25) | - | ($0.21) | ($0.18) | ($0.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.97M | $30.63M | $26.76M | $28.85M | $44.41M | $61.58M | $226.44M | $252.00M | $142.12M | $9.24M |
| Accounts Receivable | $58.0K | $6.0K | $179.0K | $225.0K | $78.0K | $116.0K | $217.0K | $142.0K | $999.0K | $1.17M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $275.35M | $148.39M | $178.50M | $195.96M | $215.74M | $231.16M | $270.17M | $294.24M | $188.20M | $16.84M |
| Total Assets | $410.77M | $266.97M | $294.82M | $310.73M | $329.35M | $341.10M | $391.15M | $385.92M | $278.29M | $97.89M |
| Current Liabilities | $31.49M | $28.68M | $20.62M | $12.99M | $12.68M | $18.23M | $28.14M | $10.61M | $14.50M | $15.66M |
| Long-term Debt | $1.61M | $1.63M | $1.64M | $1.65M | $1.66M | $1.68M | $1.69M | $1.71M | $1.71M | $1.73M |
| Total Liabilities | $63.33M | $59.94M | $52.61M | $45.03M | $44.70M | $50.43M | $62.68M | $44.92M | $48.40M | $22.71M |
| Stockholders' Equity | $347.44M | $207.03M | $242.22M | $265.69M | $284.64M | $290.67M | $328.47M | $341.00M | $229.89M | $75.18M |
| Retained Earnings | ($361.03M) | ($334.84M) | ($297.35M) | ($271.38M) | ($249.90M) | ($231.72M) | ($191.55M) | ($176.43M) | ($164.72M) | ($152.44M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($31.47M) | - | - | - | ($21.58M) | - | - | - | $13.85M | - |
| Investing Cash Flow | ($109.55M) | - | - | - | ($5.57M) | - | - | - | ($47.30M) | - |
| Financing Cash Flow | $164.36M | - | - | - | $9.97M | - | - | - | $166.33M | - |
| CapEx | $6.86M | - | - | - | $4.66M | - | - | - | $9.07M | - |
| Free Cash Flow | ($38.33M) | - | - | - | ($26.24M) | - | - | - | $4.78M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.46 | - | - | - | 1.44 | - | - | - | -0.39 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.4% | - | -8.8% | -6.9% | -5.5% | - | -3.9% | -3.0% | -4.4% | - |
| Return on equity | -7.5% | - | -10.7% | -8.1% | -6.4% | - | -4.6% | -3.4% | -5.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.75 | 5.17 | 8.66 | 15.09 | 17.02 | 12.68 | 9.60 | 27.73 | 12.98 | 1.07 |
| Quick ratio | 8.75 | 5.17 | 8.66 | 15.09 | 17.02 | 12.68 | 9.60 | 27.73 | 12.98 | 1.07 |
| Cash ratio | 1.71 | 1.07 | 1.30 | 2.22 | 3.50 | 3.38 | 8.05 | 23.75 | 9.80 | 0.59 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Debt / Assets | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.18 | 1.29 | 1.22 | 1.17 | 1.16 | 1.17 | 1.19 | 1.13 | 1.21 | 1.30 |
| Liabilities / Assets | 0.15 | 0.22 | 0.18 | 0.14 | 0.14 | 0.15 | 0.16 | 0.12 | 0.17 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.2x | - | 1.1x | 1.0x | 0.5x | - | 2.9x | 0.8x | 25.6x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -29.5% | - | -49.5% | -68.5% | -67.9% | - | -76.9% | -577.3% | -209.1% | - |
| Net income growth (YoY) | -44.1% | - | -71.7% | -83.6% | -48.0% | - | -46.0% | -5.4% | -202.0% | - |
| EPS growth (YoY) | 0.0% | - | -66.7% | -61.1% | -25.0% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -46.1% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 22.1% | -28.8% | -26.3% | -22.1% | 23.8% | 286.6% | 232.6% | 213.8% | 94.8% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Perspective Therapeutics against the 5 most active filers in the same SIC group.